Skip to main content
SpringerLink
Log in

Pharmacological Treatments

  • Chapter
  • First Online:
Handbook for Attention Deficit Hyperactivity Disorder in Adults

  • 2846 Accesses

Abstract

Drug treatment is the recommended first-line treatment for attention deficit hyperactivity disorder (ADHD) in adults.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder: NICE guideline on diagnosis and management of ADHD in children, young people and adults. NICE website. www.nice.org.uk/nicemedia/pdf/CG72NiceGuidelinev3.pdf. Accessed 25 Aug 2012.

  2. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007;21:10–41.

    Article  PubMed  CAS  Google Scholar 

  3. Kooij S. Adult ADHD diagnostic assessment and treatment. Amsterdam: Pearson; 2010.

    Google Scholar 

  4. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European network adult ADHD. BMC Psychiatry. 2010;10:67.

    Article  PubMed  Google Scholar 

  5. Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol. 2009;12:1137–47.

    Article  PubMed  Google Scholar 

  6. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96:145–54.

    Article  PubMed  CAS  Google Scholar 

  7. Koesters M, Becker T, Kilian R, Fergert JM, Weinmann S. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol. 2009;23:733–44.

    Article  PubMed  CAS  Google Scholar 

  8. Farone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004;24:24–9.

    Article  Google Scholar 

  9. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD : two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112–20.

    Article  PubMed  CAS  Google Scholar 

  10. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs. 2011;25:157–69.

    Article  PubMed  CAS  Google Scholar 

  11. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71:754–63.

    Article  PubMed  Google Scholar 

  12. British National Formulary (BNF). Methylphenidate hydrochloride. BNF website. www.bnf.org/bnf/bnf/current/86032.htm?q=methylphenidate&t=search&ss=text&p=3#_86032. Accessed 25 Aug 2012.

  13. Food and Drug Administration (FDA). FDA drug safety communication: safety review update of medications used to treat attention-deficit/hyperactivity disorder (ADHD) in adults. FDA website. www.fda.gov/Drugs/DrugSafety/ucm279858.htm. Accessed 25 Aug 2012.

  14. Poncin Y, Sukhodolsky DG, McGuire J, Scahill L. Drug and non-drug treatments of children with ADHD and tic disorders. Eur Child Adolesc Psychiatry. 2007;16(suppl 1):78–88.

    Article  PubMed  Google Scholar 

  15. Concerta Extended Release Prescribing Information. Titusville, NJ: McNeil pediatrics. www.concerta.net/sites/default/files/pdf/Prescribing_Info-short.pdf#zoom=56. Accessed 25 Aug 2012.

  16. Stifel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010;33:821–42.

    Article  Google Scholar 

  17. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196–204.

    Article  PubMed  Google Scholar 

  18. Bazire S. Psychotropic drug directory 2010: the professionals’ pocket handbook and aide memoire. Aberdeen: HealthComm UK; 2011

    Google Scholar 

  19. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005;100:96–106.

    Article  PubMed  Google Scholar 

  20. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52:456–63.

    Article  PubMed  CAS  Google Scholar 

  21. Weikop P, Egestad B, Kehr J. Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain. J Neurosci Methods. 2004;140:59–65.

    Article  PubMed  CAS  Google Scholar 

  22. Banaschewski T, Coghill D, Santosh P, et al. Long acting medications for the hyperkinetic disorders: a systematic review and European treatment guidelines. Eur Child Adolesc Psychiatry. 2006;15:476–95.

    Article  PubMed  Google Scholar 

  23. Spencer TJ, Adler LA, Weisler RH, Youcha SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced ER amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69:1437–48.

    Article  PubMed  CAS  Google Scholar 

  24. Stahl SM, Mignon L. Stahl’s illustrated attention deficit hyperactivity disorder. New York: Cambridge University Press; 2009.

    Google Scholar 

  25. Pennick M. Absorption of lisdexamphetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317–27.

    Article  PubMed  CAS  Google Scholar 

  26. Silva RR, Skimming JW, Muniz R. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder. Clin Pediatr (Phila). 2010;49:840–51.

    Google Scholar 

  27. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896–904.

    Article  PubMed  CAS  Google Scholar 

  28. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306:2673–83.

    Article  PubMed  CAS  Google Scholar 

  29. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biological Psychiatry. 2003;53:112–20.

    Article  PubMed  CAS  Google Scholar 

  30. Adler L, Dietrich A, Reimherr FW, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry. 2006;18:107–13.

    Article  PubMed  Google Scholar 

  31. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29:44–50.

    Article  PubMed  CAS  Google Scholar 

  32. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther. 2005;22:498–512.

    Article  PubMed  CAS  Google Scholar 

  33. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007;41:222–30.

    Article  PubMed  CAS  Google Scholar 

  34. Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, van Wyk GW. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. J Atten Disord. 2010;41:335–231.

    Google Scholar 

  35. Summary of product characteristics: Strattera 10 mg, 18 mg, 25 mg, 40 mg, 60 mg or 80 mg hard capsules. www.medicines.org.uk/emc/medicine/14482/SPC/Strattera++10 mg, +18 mg, +25 mg, +40 mg, +60 mg + or + 80 mg + hard + capsules/. Accessed 25 Aug 2012.

  36. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescent with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003;13:53–63.

    Article  PubMed  Google Scholar 

  37. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci. 2011;65:611–7.

    Article  PubMed  Google Scholar 

  38. Kim D, Steinhart B. Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. CJEM. 2010;12:158–61.

    PubMed  Google Scholar 

  39. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology. 2009;57:608–18.

    Article  PubMed  CAS  Google Scholar 

  40. Wuo-Silva R, Fukushiro DF, Borçoi AR, et al. Addictive potential of modafinil and cross-sensitization with cocaine: a pre-clinical study. Addict Biol. 2011;16:565–79.

    Article  PubMed  CAS  Google Scholar 

  41. Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, Weiss M. The Canadian network for mood and anxiety treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivitydisorder. Ann Clin Psychiatry. 2012;24:23–37.

    PubMed  Google Scholar 

  42. Findling RL, Greenhill LL, McNamara NK, et al. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivitydisorder. J Child Adolesc Psychopharmacol. 2007;17:433–45.

    Article  PubMed  Google Scholar 

  43. Zarinara AR, Mohammadi MR, Hazrati N, et al. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Hum Psychopharmacol. 2010;25:530–5.

    PubMed  CAS  Google Scholar 

  44. Agarwal V, Sitholey P. Combination of atomoxetine and methylphenidate in attention deficit/hyperactivity disorder: a case report. J Can Acad Child Adolesc Psychiatry. 2008;17:160.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    UKAAN

    Editor information

    Editors and Affiliations

      Rights and permissions

      Reprints and permissions

      Copyright information

      © 2013 Springer Healthcare

      About this chapter

      Cite this chapter

      UKAAN. (2013). Pharmacological Treatments. In: Handbook for Attention Deficit Hyperactivity Disorder in Adults. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-79-1_7

      Download citation

      • DOI: https://doi.org/10.1007/978-1-908517-79-1_7

      • Published:

      • Publisher Name: Springer Healthcare, Tarporley

      • Print ISBN: 978-1-908517-50-0

      • Online ISBN: 978-1-908517-79-1

      • eBook Packages: MedicineMedicine (R0)

      Publish with us

      Policies and ethics

      Search

      Navigation